Retatrutide vs SLU-PP-332
A side-by-side research comparison of Retatrutide and SLU-PP-332 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Retatrutide | SLU-PP-332 |
|---|---|---|
| Full name | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) | SLU-PP-332 (ERR Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | Research compound (preclinical) |
| Mechanism | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. | A pan-ERR (estrogen-related receptor alpha/beta/gamma) agonist. ERRs are master regulators of mitochondrial biogenesis and oxidative metabolism, so activation upregulates fat oxidation and the genetic program normally triggered by endurance exercise. |
| Molecular weight | 5,200 Da (approximate) | ~426 Da (small molecule, not a peptide) |
| Half-life | 6 days | Not well characterized in humans |
| Bioavailability | High (SubQ) | Studied via injection in animals; oral activity under investigation |
| Typical dose | 1-2 mg → titrate up to 12 mg | No established human dose |
| Frequency | Once weekly | Unknown |
| Route | Subcutaneous injection | Injection (preclinical) |
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
SLU-PP-332 reported benefits
- Increases mitochondrial fat-burning (preclinical)
- Improved endurance in animals
- Reduced fat gain without appetite change (animals)
- Acts as an "exercise mimetic"
Related comparisons
Research and educational reference only. Not medical advice.